M3 Advisory Group’s AbbVie ABBV Stock Holding History

M3 Advisory Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$531K	Sell	2,439 -19	-0.8%	-$4.21K	0.33%	58
2025 Q4	$562K	Buy	2,458 +18	+0.7%	+$4.1K	0.34%	54
2025 Q3	$565K	Buy	2,440 +115	+5%	+$23.4K	0.35%	54
2025 Q2	$431K	Buy	2,325 +33	+1%	+$6.13K	0.3%	67
2025 Q1	$480K	Sell	2,292 -45	-2%	-$8.75K	0.38%	56
2024 Q4	$415K	Buy	2,337 +7	+0.3%	+$1.29K	0.3%	73
2024 Q3	$460K	Sell	2,330 -183	-7%	-$34.2K	0.34%	70
2024 Q2	$431K	Buy	2,513 +91	+4%	+$15.1K	0.35%	66
2024 Q1	$441K	Buy	2,422 +125	+5%	+$21.5K	0.4%	57
2023 Q4	$356K	Buy	+2,297	New	+$335K	0.42%	54

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

M3 Advisory Group's ABBV Position: Q1 2026 in Review

M3 Advisory Group reduced its AbbVie (ABBV) stake by 0.77% in Q1 2026, selling an estimated $4.21K and leaving 2,439 shares worth $531K. The position accounts for 0.33% of the portfolio, ranked #58.

M3 Advisory Group first reported a position in ABBV in Q4 2023 and has held it in 10 quarters since. The position peaked at $565K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

M3 Advisory Group held 2,439 shares of AbbVie worth $531K as of Q1 2026.
M3 Advisory Group sold 19 AbbVie shares in Q1 2026, an estimated $4.21K.
AbbVie made up 0.33% of M3 Advisory Group's portfolio in Q1 2026, its #58 holding.
M3 Advisory Group first reported a position in AbbVie in Q4 2023 and has held it in 10 quarters since.
M3 Advisory Group's AbbVie position peaked at $565K in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on M3 Advisory Group's 13F filing for Q1 2026, filed 22 Apr 2026.